Compliance With Post-Approval Commitments Goes Public On CDRH Web Site
This article was originally published in The Gray Sheet
Executive Summary
A Web site that will publicly display the status of FDA-required post-approval medical device studies will be operational within weeks, according to Steven Chasin, deputy director of the postmarket surveillance division at CDRH's Office of Surveillance & Biometrics
You may also be interested in...
No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6
A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6
No More Secrets: CDRH Post-Approval Study Web Site Goes Live April 6
A public Web site tracking device companies' progress on FDA-required post-approval studies is scheduled to go live April 6
Interim Postmarket Data Release May Compromise Trials – FDA Panel
Members of FDA's Neurological Devices Panel questioned the wisdom of asking sponsors to present interim results of ongoing post-approval trials during a meeting Jan. 26